Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

CODX vs AYTU: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

AYTU Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 7–3 Matrix Metrics)

AYTU Overall Winner 6-Pillar Tally: CODX 1 – 5 AYTU Matrix Metrics: CODX 3 – 7 AYTU

As of Nov 16, 2026, AYTU BioPharma, Inc. (AYTU) is the stronger overall head-to-head candidate over Co-Diagnostics, Inc. (CODX) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). CODX carries a Unified Composite Score of 51.6/100 (HOLD) at $0.23 (15.4x Forward P/E, -3415.8% operating margin), whereas AYTU carries 48.9/100 (HOLD) at $1.81 (9.2x Forward P/E, -14.4% operating margin).

  • Composite vs. Pillar Nuance: While CODX currently prints a higher short-term Unified Composite Score (51.6/100 HOLD vs. AYTU 48.9/100 HOLD), AYTU captures the overall institutional head-to-head verdict (7–3 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (-14.4% vs. -3415.8% operating margin) and revenue trajectory (+6.4% vs. +94.6% YoY).
  • Technical & Structure Timing Caution: CODX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 21.7); meanwhile AYTU is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CODX vs AYTU
CODX NASDAQ
Co-Diagnostics, Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$0.23
-11.68% 1D
Market Cap $2.3M
TTM Revenue $858,888
Forward P/E 15.4x
Beta / 30D Vol 2.93β · 148% Vol
Unified Composite Score
51.6 / 100 HOLD
Tech 55.0 Fund 54.0 Flow 66.0 Mom 40.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -31.1%), weak momentum, RSI 22
RSI-14: 21.7 · SMA20: $0.39 · SMA50: $0.78
AYTU NASDAQ Head-to-Head Winner
AYTU BioPharma, Inc. Common Stock
Pharmaceutical Preparations
$1.81
+1.69% 1D
Market Cap $19.6M
TTM Revenue $58M
Forward P/E 9.2x
Beta / 30D Vol 0.65β · 35% Vol
Unified Composite Score
48.9 / 100 HOLD
Tech 49.0 Fund 53.0 Flow 50.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -7.8%), weak momentum, RSI 38
RSI-14: 37.7 · SMA20: $1.89 · SMA50: $2.00

6-Pillar Scorecard Institutional Category Breakdown (CODX 1 – 5 AYTU)

Columns: Metric · CODX · AYTU
1. Valuation Multiples AYTU
Forward P/E 15.4x 9.2x
Trailing P/E 15.4x 9.2x
PEG Ratio N/M N/M
EV / Revenue N/M 0.3x
2. Growth & Scale CODX
Revenue Growth (YoY) +94.6% +6.4%
Earnings Growth (YoY) +30.8% +0.0%
TTM Revenue (USD) $858,888 $58M
Market Cap $2.3M $19.6M
3. Profitability & Quality AYTU
Gross Margin 20.3% 64.0%
Operating Margin -3415.8% -14.4%
Net Profit Margin 0.0% -24.8%
Return on Equity (ROE) -192.8% -52.5%
4. Balance Sheet & Cash Flow AYTU
Cash Generation (TTM) -$28M EBITDA -$1.4M
Cash Flow Margin N/A -2.4%
Net Cash / Leverage $6.2M Net Cash $4.9M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning AYTU
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 270.2% (50th %ile) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase DISTRIBUTION · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat AYTU
OpEx & R&D Intensity N/A 78.4% of Rev ($45M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Drug Manufacturers - Specialty & Generic Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CODX (3) vs AYTU (7)
Institutional Metric CODX AYTU Criterion Row Edge
Market Capitalization
Scale
$2.3M $19.6M Larger Scale AYTU
Trailing P/E Ratio
Valuation
15.4x 9.2x Lower Multiple AYTU
Forward P/E Ratio
Valuation
15.4x 9.2x Lower Multiple AYTU
Revenue Growth (YoY)
Growth
+94.6% +6.4% Higher Growth CODX
Operating Margin (TTM)
Profitability
-3415.8% -14.4% Higher Margin AYTU
Net Profit Margin
Profitability
0.0% -24.8% Higher Margin CODX
Return on Equity (ROE)
Capital Efficiency
-192.8% -52.5% Higher ROE AYTU
52-Week Range Position
Momentum
0% ($0–$14) 5% ($2–$3) Stronger Trend AYTU
Beta / 30D Volatility
Risk Regime
2.93β · 148% Vol 0.65β · 35% Vol Lower Realized Risk AYTU
Unified Institutional Score
Composite Signal
51.6 / 100 (HOLD) 48.9 / 100 (HOLD) Higher Composite CODX
Trailing 12M Revenue (USD)
Operating Scale
$858,888 $58M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
20.3% 64.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 0.3x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$28M EBITDA ($6.2M Net Cash) -$1.4M ($4.9M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon AYTU +53.81 pp
CODX: -65.08% · AYTU: -11.27%
3M Horizon AYTU +58.56 pp
CODX: -81.87% · AYTU: -23.31%
6M Horizon AYTU +69.52 pp
CODX: -83.33% · AYTU: -13.81%
1Y Horizon AYTU +26.46 pp
CODX: -38.6% · AYTU: -12.14%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period CODX Revenue AYTU Revenue CODX Op. Margin AYTU Op. Margin Margin Leader
FY2019 $0M $10M -2741.6% -230.1% AYTU
FY2020 $70M $30M 55.9% -76.5% CODX
FY2021 $100M $70M 47.1% -89.7% CODX
FY2022 $30M $100M -78.8% -113.7% CODX
FY2023 $10M $110M -626.9% -15.9% AYTU
FY2024 $0M $70M -1023.7% -2.4% AYTU
FY2025 $0M $70M -8058.8% -11.8% AYTU
FY2026 N/A $60M N/A -14.4% AYTU

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CODX BREAKDOWN
173d in phase · OBV DISTRIBUTION
Current IV 270.2%
IV Percentile 50th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact CODX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
AYTU UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact AYTU Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CODX Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $2.3M market capitalization and -3415.8% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
AYTU Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $19.6M market capitalization and -14.4% operating margin.
OpEx & R&D Reinvestment 78.4% of Rev ($45M)
90D Engineering Disclosures 0 Published

Investor FAQ CODX vs AYTU Key Questions & Quantitative Answers

As of Nov 16, 2026, AYTU BioPharma, Inc. (AYTU) is the stronger overall head-to-head candidate over Co-Diagnostics, Inc. (CODX) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). CODX carries a Unified Composite Score of 51.6/100 (HOLD) at $0.23 (15.4x Forward P/E, -3415.8% operating margin), whereas AYTU carries 48.9/100 (HOLD) at $1.81 (9.2x Forward P/E, -14.4% operating margin). Composite vs. Pillar Nuance: While CODX currently prints a higher short-term Unified Composite Score (51.6/100 HOLD vs. AYTU 48.9/100 HOLD), AYTU captures the overall institutional head-to-head verdict (7–3 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (-14.4% vs. -3415.8% operating margin) and revenue trajectory (+6.4% vs. +94.6% YoY). Technical & Structure Timing Caution: CODX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 21.7); meanwhile AYTU is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CODX leads the Growth & Scale pillar: CODX posts +94.6% YoY revenue growth and +30.8% YoY earnings growth on $858,888 TTM revenue (20.3% gross margin, -3415.8% operating margin), compared with AYTU at +6.4% YoY revenue growth and +0.0% YoY earnings growth on $58M TTM revenue (64.0% gross margin, -14.4% operating margin). Across the 8-period historical trajectory (FY2019 to FY2026), CODX cumulative revenue shifted -85.7% while AYTU shifted +500.0%. In operating R&D and SG&A reinvestment, CODX deploys N/A (0 90-day corporate R&D disclosures) versus 78.4% of Rev ($45M) (0 disclosures) for AYTU.

AYTU screens cheaper on headline valuation multiples. CODX trades at 15.4x Forward P/E, 15.4x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported EBITDA margin), whereas AYTU trades at 9.2x Forward P/E, 9.2x Trailing P/E, N/M PEG, and 0.3x EV/Revenue (-2.4% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CODX (-192.8% ROE) versus AYTU (-52.5% ROE) capital efficiency.

In options market volatility and institutional positioning, CODX carries 270.2% implied volatility (50th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (2.93β · 148% Vol realized risk). By comparison, AYTU carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.65β · 35% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.